American Academy of Stem Cell Physicians To Host 1st Virtual Congress & Safety Panel (August 1-2, 2020)
While COVID-19 has caused many events to be rescheduled, a highly anticipated and sought after American Academy of Stem Cell Physicians (AASCP) meeting is back by popular demand. Over August 1-2, 2020, the AASCP will host its first virtual congress, allowing for wide-scale participation at an unprecedented scale. The Academy is expecting 5,000 attendees, as the program will be broadcasting internationally.
AASCP Virtual Congress Safety Panel Dr. Farshchian teaching at the AAOSCP workshop. Due to COVID-19, the meeting will take place virtually. This is an effective way to ensure that everyone that wishes to participate―including those who cannot travel―can be involved. It will be readily accessible and economical, so that students, educators and physicians will not miss out on all the important topics that AASCP has in the pipeline.
Over August 1-2, 2020, the AASCP will present virtual interactive workshops that feature small participant-to-instructor ratios with a customized curriculum focusing on developing hands-on skills. Each technique will be taught by experts in the field, using didactic sessions with dynamic multimedia presentations, live demonstrations and scanning on live model, as well as phantoms.
The medical device industry is in a constant state of expansion and reshaping, with an abundance of opportunities for innovation creating an environment in which companies must continuously add to a product portfolio in order to remain competitive. Now, corporate strategy executives must evaluate the impact of COVID-19 on the global economy determine how business objectives will evolve in 2020 and beyond. In this virtual event, industry leaders will come together to add resources to the company toolbox and ensure strategy teams act as drivers of value and cost-consciousness internally as well as strategic partners within the healthcare space. Corporate strategy executives will share lessons learned on past and potential business deals, growth strategies, negotiation techniques, and decisions surrounding calculations for increased return on investment. As the industry relies on both organic and inorganic growth, it is imperative for industry leaders to continuously implementing novel ideas and business plans.
New regulations: After the implementation of the new “Drug Management Law”, ICH, and the “Drug Management Law”, what legal talents are required to understand clinical, registration and production? New opportunities: Rare diseases, cancer drugs, cells, and gene therapy are on the rise. How can companies improve their R&D expertise? New Ecology: After taking volume purchases and new medical insurance policies, how does the new drug research and development community formulate market access strategies in advance? New challenge: How to balance the high cost of clinical research and development and the quality of trials under the premise of early market access intervention?
August 29, 2020, at the Washington DC office of Foley & Lardner LLP, 3000 K Street, NW, Suite 600, Washington, DC, 20007.
In prior years, multiple SAPA chapters have successfully organized similar events around the US that connected emerging companies in the biopharma, medical device, and diagnostics industries with leading global investors. SAPA-DC is excited to become the latest SAPA chapter to join this effort and contribute to accelerating scientific innovation and entrepreneurship in the greater Washington DC area.